Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Management of melanoma in 2030: Toxicity, resistance, best biomarkers and next steps

Future combinations: Intralesional and other immunotherapy combinations

Date

18 Oct 2020

Session

Management of melanoma in 2030: Toxicity, resistance, best biomarkers and next steps

Topics

Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Olivier Michielin

Authors

O.A. Michielin

Author affiliations

  • Oncology, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.